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Introduction 
 Atherosclerosis is a chronic inflammatory disease of blood vessels. Macrophages 
are present at all stages of the disease and facilitate cholesterol accumulation that can lead to 
atherosclerotic lesion formation and myocardial infarction (Fig.1) [1-4]. The uptake of low 
density lipoprotein (LDL) is a critical process in the development of atherosclerosis, and 
both LDL and modified LDL were found in atherosclerotic lesions [5]. The uptake of native 
LDL by M-CSF-differentiated macrophages occurs by receptor-independent pathways 
including macropinocytosis and micropinocytosis with both pathways promoting 
macrophage cholesterol accumulation [6]. Oxidized LDL (OxLDL) is recognized by 
scavenger receptors [7] such as class A scavenger receptor (scavenger receptor class A type I, 
SR-AI) [8] and class B scavenger receptor (cluster of differentiation 36, CD36) [9], and 
taken up by macrophages also promoting cholesterol accumulation. However, LDL isolated 
from human aorta is not oxidized sufficiently to be taken up into macrophage through 
scavenger receptors [10], and macrophages incubated with OxLDL mostly accumulated 
cholesterol in lysosomes rather than in lipid droplet [11]. Thus, we expected that another 
LDL uptake system exists in macrophages to form lipid droplets. 
 Acrolein is a highly reactive alpha, beta-unsaturated aldehyde, and mainly produced 
by polyamine oxidation [12]. Production of acrolein derived from polyamines by polyamine 
oxidases is increased during cell damage such as renal failure [13], stroke [14-16] and 
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Alzheimer's disease [17]. Acrolein is spontaneously formed from 3-aminopropanal 
[NH2(CH2)2CHO] produced from spermine by spermine oxidase (SMO), and less efficiently 
from 3-acetamidopropanal [CH3CONH(CH2)2CHO] produced from spermine and 
spermidine by N1-spermidine/spermine N1-acetyltransferase and acetylpolyamine oxidase 
(AcPAO) [18-20]. Acrolein can also be formed from arachidonic acid [21], but its production 
by this route is inefficient [22], supporting the idea that acrolein is mainly produced from 
polyamines. Acrolein is also produced from overheated organic matter [23], such as 
incomplete combustion of plastic materials, cigarette smoking, and overheating frying oils. 
Recent estimates show that high levels of acrolein (between 6 and 8 part per million [ppm]) 
are present in exhaust gases from petrol and diesel engine vehicles [24] and that up to 50 
to70 ppm acrolein is generated in tobacco smoke (100 to 600 µg/cigarette) [23]. Acrolein has 
a high reactivity with proteins, and protein-conjugated acrolein was detected in human 
atherosclerotic lesions using an acrolein-recognized antibody [25]. One of the acrolein 
derivatives, i.e. Nε-(3-methylpyridinium)lysine (MP-Lys) was detected in apolipoprotein B 
(apoB) of native LDL using LC-MS/MS [26]. It has been also reported that 
protein-conjugated acrolein detected in plasma from patients with carotid atherosclerosis 
[27] or hyperlipidemia [28] using ELISA system. These findings suggest that acrolein may 
contribute to LDL modification resulting macrophage foam cell formation and atherogenesis. 
Cholesteryl ester (CE) in lipoproteins is metabolized as follows (Fig. 2) [29]. When 
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lipoproteins are delivered to lysosomes after cell uptake, apoB is digested by lysosomal 
protease [30] and CE is hydrolyzed to free cholesterol (FC) and fatty acid by acid cholesterol 
esterase (ACEase) [31]. The FC is transported to endoplasmic reticulum (ER), converted to 
CE by acyl-CoA: cholesterol acyltransferase (ACAT) [32, 33], and stored as lipid droplets 
within the cytosol [34]. CE in lipid droplets is hydrolyzed by neutral cholesterol esterase 
(NCEase) [35, 36] and FC is effluxed to acceptors like high density lipoprotein (HDL) via 
ATP-binding cassette transporters [37, 38]. Macrophages show not only higher activities of 
ACEase and ACAT but also lower activity of NCEase, contributing to the accumulation of 
CE in lipid droplets [35, 36, 39]. 
 In this study, we examined whether acrolein-conjugated LDL (Acro-LDL) is 
effectively taken up into macrophages converting them into foam cells. We found that foam 
cell formation did indeed occur through uptake of Acro-LDL that resulted in the 
accumulation of CE in lipid droplets. 
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Fig. 1.  Foam cell formation in atherosclerotic lesions. 
SMC, smooth muscular cells; LDL, low density lipoprotein; βVLDL, β-migrating very low 
density lipoprotein. 
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Fig. 2.  Lipoprotein -cholesterol metabolism in macrophages. 
C, cholesterol; CE, cholesterol ester; ACEase, acid cholesterol esterase; ER, endoplasmic 
reticulam; ACAT, acyl CoA: cholesterol acyltransferase; NCEase, neutral cholesterol 
esterase; HDL, high density lipoprotein; ABC transport protein, ATP binding cassette 
transport protein. 
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Materials and methods 
Materials 
 Acrolein was purchased from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). 
Phorbol 12-myristate 13-acetate (PMA), bovine serum albumin (BSA) and 
1,1’-Dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine perchlorate (DiI) were obtained 
from Sigma-Aldrich Co. LLC. (St. Louis, MO, USA). RPMI-1640 medium (RPMI) was 
obtained from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Fetal bovine serum 
(FBS) was obtained from Hyclone (Tauranga, New Zealand). 
 
Cell culture 
 A human cell line established from acute monocytic leukemia cells, THP-1 cells 
(ATCC), was maintained in RPMI containing heat-inactivated 10% FBS, 100 U/mL 
penicillin and 100 µg/mL streptomycin (Life Technologies Corporation). THP-1 cells (1.0 x 
106 cells/mL) were treated with 150 nM PMA for 2 days in RPMI containing 10% FBS, and 
the adherent cells were used as macrophages referred to as THP-1 macrophages in this 
manuscript [40]. 
 
Anti-acrolein antibodies 
 Both monoclonal antibody (mAb5F6, NOF corporation), which recognizes 
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Nε-(3-formyl-3,4-dehydropiperidino)lysine (FDP-Lys) [25] as well as MP-Lys [41], and 
polyclonal antibody (1049GE, MoBiTec), which recognizes acrolein derivatives of various 
amino acids such as Lys, His, Arg and Cys [42-45], were used for western blotting. 
 
Preparation of lipoproteins 
 Very low density lipoprotein (VLDL), low density lipoprotein (LDL), high density 
lipoprotein (HDL) and lipoprotein-deficient plasma (LPDP) were isolated from human 
plasma by sequential ultracentrifugation and were dialyzed against 20 mM Tris-HCl (pH 7.4), 
2 mM EDTA, 0.15 M NaCl and 0.02% NaN3 for 4 h, 3 times [46]. Informed consent was 
given by each subject, and the study protocol was approved by the ethics committees of the 
Graduate School of Pharmaceutical Science, Chiba University. 
 
Modification of lipoproteins by acrolein 
 Modification by acrolein of 2 mg protein/mL of lipoproteins was performed by 
incubation with indicated concentrations of acrolein at 37°C for 24 h under nitrogen gas. 
Then, to remove free acrolein, modified lipoproteins were dialyzed against 0.9% NaCl for 4 
h, 3 times, and then against RPMI. Acrolein-conjugated lipoproteins (Acro-lipoproteins) 
were filtered through 0.45 µm Pore SFCA membrane syringe filters, before use in 
experiments. 
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 Preparation of oxidized LDL 
 In order to remove the EDTA, 2 mg protein/mL LDL was first dialyzed 3 times 
against phosphate buffered saline (PBS) for 4 h. To oxidize LDL, the LDL was incubated 
with 50 µM CuSO4 at 37°C for 16 h. To end the oxidation, the LDL was dialyzed 3 times 
against 0.9% NaCl containing 1 mM EDTA for 4 h. After dialysis against RPMI, following 
oxidized LDL (OxLDL) was filtered through 0.45 µm Pore SFCA membrane syringe filters, 
before use in experiments. 
 
Agarose gel electrophoresis of lipoproteins 
 Agarose gel electrophoresis was performed in barbital buffer solution (Mitsubishi 
Chemical Medience Corporation) using universalgel/8 (Helena). The gel was stained with 
Fat Red 7B (MP Biomedicals, LLC.). 
 
Determination of protein concentration 
 Protein concentrations were determined using BCA protein assay reagent kit 
(Thermo Fisher Scientific). BSA was used as the standard in this assay. 
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Determination of cellular cholesterol content 
 Cellular cholesterol content was measured as follows [36]. Cells were seeded at a 
concentration of 1.0 x 106 cells/well. On day 2, each well received 1 ml of RPMI containing 
2% FBS and lipoproteins at a concentration described in each experiments. On day 4, each 
well was rinsed twice with 1 ml of cold PBS containing 0.1% BSA, 0.9 mM CaCl2 and 0.33 
mM MgCl2, then rinsed twice with 1 ml of cold PBS with 0.9 mM CaCl2 and 0.33 mM 
MgCl2, and then finally treated with 1 mL hexane/isopropanol (2:1). After incubation for 1 h, 
the organic solvent was collected and evaporated. The lipid residue was dissolved in 50 µL 
95% ethanol, and the total and free cholesterol contents in the solution were assayed. Total 
and free cholesterol concentrations were determined using Total cholesterol E-test and Free 
cholesterol E-test (Wako Pure Chemical Industries), respectively. Cholesteryl ester 
concentrations were determined as the difference between total and free cholesterol 
concentrations. 
 
Determination of malondialdehyde contents 
 Malondialdehyde contents were determined by the following method [47]. For each 
determination, 20 µL of 20% trichloroacetic acid was added to 60 µL of samples and the 
samples were incubated on ice for 10 min. After centrifugation at 16,100 x g for 20 min, 60 
µL of the supernatant was added to 10 µL of 0.1125 M HClO4 and 10 μl of 40 mM 
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2-thiobarbituric acid (Sigma-Aldrich) (final 14.1 mM HClO4, 5 mM 2-thiobarbituric acid). 
The reaction mixture was then vortexed and incubated at 94 °C for 60 min. The reaction 
mixture was measured at 532 nm. Malondialdehyde standards were prepared from the 
hydrolysis of 1,1,3,3-tetraethoxypropane (Sigma-Aldrich). 
 
Western blot analysis 
 Detection of protein-conjugated acrolein, apolipoprotein B (apoB), CD36, SR-A1, 
lysosomal-associated membrane protein 1 (LAMP-1), glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) and β-actin were carried out by western blotting. To detect 
protein-conjugated acrolein, both monoclonal antibody (mAb5F6, NOF corporation), which 
recognizes FDP-Lys [48] as well as MP-Lys [41], and polyclonal antibody (1049GE, 
MoBiTec), which recognizes acrolein derivatives of various amino acids such as Lys, His, 
Arg and Cys [16], were used. The cells were washed twice with cold PBS. Cells were lysed 
in a buffer [20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.5% Triton X-100, 0.5% sodium 
deoxycholate, 10 mM EDTA, 10 µM FUT-175, 10 µM E-64-c, 0.5 mM sodium 
orthovanadate, 0.1 mM NaF] for 20 min on ice. Cell lysates were centrifuged at 16,100 x g 
for 20 min, and protein concentrations determined. Cell lysate or lipoproteins were separated 
on 6%, or 8% Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), 
proteins were transferred to an Immobilon membrane (Millipore) and immunoblotted with 
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specific antibodies. Immunoblots were visualized by Immobilon™ Western (Millipore). The 
antibodies used for western blotting were monoclonal and polyclonal anti-acrolein antibodies, 
polyclonal anti-apoB antibody (sc-25542, Santa Cruz), polyclonal anti-CD36 antibody 
(sc-9154, Santa Cruz), monoclonal anti-SR-A1 antibody (SRA-C6, Abnova), polyclonal 
anti-β-actin antibody (sc-1616-R, Santa Cruz), monoclonal anti-LAMP-1 antibody (sc-20011, 
Santa Cruz), polyclonal anti-GAPDH antibody (sc-25778, Santa Cruz) as primary antibodies. 
Membranes were incubated for 3 h. Membranes were treated 30 min with anti-mouse, or 
anti-rabbit IgG (horseradish-peroxidase-linked species-specific antibody; GE Healthcare UK 
Ltd.) as the secondary antibody. 
 
Preparation of DiI-labeled lipoproteins 
 DiI-labeled lipoproteins were prepared by the following method [49]. Lipoproteins 
were incubated on ice for 30 min with 0.2 mg of DiI in dimethyl sulfoxide (DMSO) (5 
mg/ml) per mg of lipoproteins. Unbound dye was removed by passing labeled lipoproteins 
through Sephadex G-75 (1.6 cm x 5 cm). DiI-labeled lipoproteins (DiI-lipoproteins) were 
filtered with 0.45 µm Pore SFCA membrane syringe filters, before use in experiments. 
 
Antibody inhibition of DiI-lipoprotein uptake by THP-1 macrophages 
 THP-1 macrophages were pre-incubated with 20 µg/mL anti-SR-A1 antibody 
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and/or anti-CD36 antibody (clone FA6.152, Abnova) in RPMI containing 2% FBS for 1 h. 
These antibodies were commercially supplied as neutralizing antibodies [50, 51]. Purified 
IgG from mouse serum (Sigma) was used as control IgG. Then, macrophages were incubated 
with 10 µg protein/mL DiI-labeled Acro-LDL or DiI-labeled OxLDL for 2 h. After 
incubation, macrophages were lysed with 0.1% Triton X-100 in PBS, fluorescent intensity 
was determined (Excitation, 544 nm; Emission, 590 nm). 
 
Competition assay for DiI-labeled Acro-LDL uptake using acetylated LDL 
 To acetylate LDL, LDL was diluted with equal volume of saturated sodium acetate. 
Then acetic anhydride was added to LDL solution slowly (5 µL/mg protein). After stirring 
for 1 h on ice, the LDL was dialyzed 3 times against 0.9% NaCl containing 1 mM EDTA for 
4 h. After dialysis against RPMI, following acetylated was filtered through 0.45 µm Pore 
SFCA membrane syringe filters, before use in experiments. 
 To assess competition for uptake of DiI-labeled Acro-LDL by acetylated LDL, 
macrophages were pretreated with RPMI containing 2% FBS for 1 h, and then incubated 
with 10 µg protein/mL DiI-labeled Aceo-LDL and 1 – 100 µg protein/mL acetylated LDL or 
Acro-LDL. After incubation, macrophages were lysed with 0.1% Triton X-100 in PBS, 
fluorescent intensity was determined (Excitation, 544 nm; Emission, 590 nm). 
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Confocal microscopy 
 For detection of DiI-labeled lipoprotein and lysosomes, THP-1 macrophages were 
cultured as described above on glass bottom dishes. After DiI-labeled lipoprotein treatment, 
living cells were rinsed twice with RPMI, and then stained 1 min with 150 nM LysoTracker 
(Invitrogen) at 37°C. 
 For double staining of lipid droplets and lysosomes, THP-1 macrophages were 
cultured on glass bottom dishes as described above. After Acro-LDL or OxLDL treatment, 
cells were treated with 100 ng/mL Nile Red at room temperature for 5 min, and then 150 nM 
LysoTracker at 37°C for 1 min. 
 Photographs were taken with a Fluoview FV500 confocal laser scanning 
microscope (Olympus, Tokyo). 
 
Fractionation of lysosome from THP-1 macrophages 
 THP-1 macrophages were incubated with 50 µg protein/mL Acro-LDL for 48 h. The 
cells were rinsed twice with PBS and suspended in fractionation buffer [5 mM Tris-HCl (pH 
7.4), 0.25 M sucrose, 1 mM EDTA]. The cell suspension was homogenized with 
homogenizer in an ice bath. The homogenate was centrifuged at 900 x g for 10 min at 4°C, 
and the pellet was collected as nuclear fraction. The post-nuclear supernatant was 
centrifuged at 5,000 x g for 10 min at 4°C, and the pellet was collected as mitochondria 
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fraction. The post-mitochondria supernatant was centrifuged at 8,000 x g for 10 min at 4°C, 
and the pellet was collected as lysosome fraction. The lysosome fraction was suspended in IP 
buffer, and used for western blotting. 
 
ApoB digestion by lysosomal enzymes of THP-1 macrophages 
THP-1 macrophages were collected at 48 h after PMA treatment. The cells were 
rinsed twice with PBS and suspended in ST buffer [50 nM Tris-HCl (pH 7.4), 0.25 M 
sucrose]. The cells were sonicated three times for 15 seconds on ice, and used as an enzyme 
source. LDL and Acro-LDL prepared with 2 or 5 mM acrolein containing 20 µg protein were 
incubated with 30 µg of cell lysate at acidic condition (pH 4.5) for the indicated times at 
37 °C. The reaction was stopped by the addition of SDS-PAGE sample buffer. Then, reaction 
mixtures were incubated at 98 °C for 90 sec. After western blotting, anti-apoB antibody was 
used for detection. 
 
Preparation of enzyme source for enzyme assay 
 THP-1 macrophages were rinsed twice with PBS and suspended in SET buffer [50 
nM Tris-HCl (pH 7.4), 0.25 M sucrose, 1 mM EDTA]. The cells were sonicated 3 times for 
15 seconds on ice, and used for enzyme assay. 
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Assay of ACEase and NCEase activities 
 Substrate particles were prepared as follows [52]. A total of 1.6 mg cholesteryl 
oleate, 185 kBq cholesteryl [14C]oleate (3.7 MBq/mL; American Radiolabeled Chemicals, 
Inc) and 2.3 mg phosphatidylcholine were mixed thoroughly and dried under nitrogen gas. 
Two mL of 0.9% NaCl was added to the lipid mixture that was then sonicated 15 min in an 
ice bath. This substrate reaction mixture contained 40 µL substrate, enzyme (100–200 µg 
protein), and 10 mM Acetate buffer (pH 4.5) or 10 mM Tris–HCl (pH 7.4), in a total volume 
of 200 µL. Final substrate concentration in the reaction mixture was 255 µM cholesteryl 
oleate and 613 µM phosphatidylcholine. The reaction mixture was incubated for 3 h at 37°C. 
The enzymatic release of [14C]oleate was stopped by the addition of 3.25 mL 
chloroform:methanol:heptane (1.42:1.25:1.00) [53], followed by 1 mL 0.1 M NaOH. The 
radioactivity of the water phase was counted. 
 
Assay of ACAT activity in vitro 
 ACAT activity in vitro was assayed by the method of Gillies et al. [54] using 
[1-14C]oleoyl-CoA (1.85 MBq/mL; Amersham bioscience) without additional cholesterol. 
For each assay employed, the assay was initiated by adding 20 µL of solution containing 10 
nmol of [1-14C]oleoyl-CoA and 10 nmol of fatty acid-free BSA. The reaction mixture was 
incubated at 37 °C for 30 min because the enzyme activity was linear with time until 45 min. 
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Lipids were extracted from the reaction mixture using cholorform:methanol (2:1). 
Cholesterol [14C]oleate was separated by thin-layer chromatography (Macherey-Nagel 
GmbH & Co. KG) and measured. 
 
Statistical analysis 
 Data are shown as mean ± SE. Statistical significance was evaluates by student’s 
t-test, Tukey’s test or Dunnett's test. 
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Results 
Acro-LDL-induced cholesterol accumulation in THP-1 macrophages 
In order to examine the effect of acrolein on macrophage foam cell formation, 
Acro-lipoproteins were prepared. Compared with intact lipoproteins, the mobilities of 
Acro-lipoproteins in agarose gel electrophoresis were increased as with OxLDL (Fig. 3). 
This result suggests that the charge of Acro-lipoproteins were more negative than that 
of intact lipoproteins. To clarify whether lipid peroxidation occurred during 
acrolein-modification, malondialdehyde contents of intact lipoproteins and Acro-lipoproteins 
were determined (Table 1). Although malondialdehyde in OxLDL was 17.4-fold higher than 
that in LDL, malondialdehyde in Acro-lipoproteins was nearly equal to that in intact 
lipoproteins. The results indicate that lipid peroxidation did not occur during preparation of 
Acro-lipoproteins, and the increase in the mobility of Acro-lipoproteins was due to acrolein 
modification, but not due to lipid peroxidation. 
Total cholesterol (TC), free cholesterol (FC) and CE contents in THP-1 
macrophages incubated with Acro-LDL were 2.0-, 1.4-, and 9.7-fold higher than the contents 
in THP-1 macrophages incubated with LDL, respectively. CE content of THP-1 
macrophages incubated with Acro-LDL was 1.4-fold higher than that of THP-1 macrophages 
incubated with OxLDL. When THP-1 macrophages were incubated with HDL or Acro-HDL, 
accumulation of cholesterol was not observed (Fig. 4). 
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The increase of the cholesterol contents in THP-1 macrophages induced by 
incubation with varying concentrations of LDL, OxLDL or Acro-LDL was determined (Fig. 
5). TC and CE contents in THP-1 macrophages were significantly increased at all 
concentrations of Acro-LDL compared with macrophages not incubated with any lipoprotein, 
and were greater than the increases observed with OxLDL and LDL. At the highest 
concentration (200 µg protein/mL) TC and CE contents of macrophages incubated with 
Acro-LDL were 1.8- and 3.5- fold higher compared with macrophages incubated with LDL, 
and were 1.2- and 2.1-fold higher compared with macrophages incubated with OxLDL. 
Increase of FC content by Acro-LDL was similar to that by OxLDL, and both were greater 
than the FC content induced by incubation of macrophages with LDL. Cholesterol contents 
in THP-1 macrophages incubated with 20 µg protein/mL Acro-LDL increased in a 
time-dependent manner (Fig. 6). These results indicate that Acro-LDL is a more potent 
inducer of CE accumulation in THP-1 macrophage than OxLDL. 
Because it is thought that acrolein mainly interacts with apoB in LDL, properties of 
apoB in native LDL, OxLDL and Acro-LDL were examined by western blotting using 6% 
polyacrylamide gel (Fig. 7) and 3 – 10% gradient gel (Fig.8). In detection of 
acrolein-conjugated apoB, both monoclonal and polyclonal antibodies were used. ApoB in 
native LDL showed an apparent molecular weight 500 kDa or more than 1,000 kDa, but 
apoB in OxLDL was partially degraded. Acrolein-conjugated apoB was observed in native 
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LDL and OxLDL using polyclonal antibody against acrolein. When LDL was treated with 2 
and 10 mM acrolein, almost all apoB was more than 1,000 kDa, suggesting the cross-linking 
of apoB by acrolein. The intensity of apoB detected with anti-acrolein antibody for LDL 
treated with 10 mM acrolein was decreased compared with apoB of LDL treated with 2 mM 
acrolein, suggesting that structural change of apoB due to the increase in the degree of 
acrolein-modification showed decreased reactivity against anti-acrolein antibody. Also, apoB 
intensity detected with anti-apoB antibody decreased when LDL was treated with 10 mM 
acrolein. The results suggest that Acro-LDL is taken up into THP-1 macrophages through the 
recognition of acrolein-modified apoB. 
Next, we examined the effect of increasing acrolein concentration (0.2 – 10 mM) on 
the increase in LDL electrophoretic mobility. Agarose gel electrophoresis showed that 
Acro-LDL’s increase in mobility was concentration-dependent (Fig. 9). The effect of 
acrolein concentration on the degree of the increase of cholesterol contents in THP-1 
macrophages incubated with Acro-LDL was determined (Fig. 10). The increase in 
cholesterol content was almost linear between 1 and 5 mM acrolein and reached a plateau 
with the cholesterol content in THP-1 macrophages being nearly equal with 5 and 10 mM 
acrolein-treated LDL. 
To clarify whether THP-1 macrophages uptake Acro-LDL, apoB and 
protein-conjugated acrolein in THP-1 macrophages incubated with Acro-LDL were detected 
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by western blotting (Fig. 11). Detected band cross-reacted anti-ApoB antibody in THP-1 
macrophages incubated with LDL was almost 500 kDa, and the band in THP-1 macrophages 
incubated with Acro-LDL was more than 1,000 kDa. Protein-conjugated acrolein using 
monoclonal and polyclonal antibody for acrolein was also detected in THP-1 macrophages 
incubated with Acro-LDL. These data suggest that THP-1 macrophages uptake Acro-LDL, 
resulting to cholesterol accumulation in THP-1 macrophages. 
 
Pathway of Acro-LDL uptake by THP-1 macrophages 
 We tested whether SR-A1 and/or CD36 recognize Acro-LDL. As shown in Fig. 12A, 
CD36 was uniformly expressed in THP-1 macrophage regardless of treatment with LDL or 
Acro-LDL. However, the expression of SR-A1 in THP-1 macrophages increased when the 
macrophages were incubated with LDL and Acro-LDL. Next, we measured the uptake of 
DiI-labeled Acro-LDL and DiI-labeled OxLDL by THP-1 macrophage in the presence and 
absence of antibodies against CD36 and SR-A1. As shown in Fig. 12B, the uptake of both 
DiI-labeled Acro-LDL and DiI-labeled OxLDL was strongly inhibited by antibody against 
SR-A1, but not by antibody against CD36, indicating that SR-A1 is mainly involved in the 
uptake of Acro-LDL and OxLDL by THP-1 macrophages. 
It has been reported that acetylated LDL is recognized by SR-AI. Thus we examine 
whether acetylated LDL compete with DiI-labeled LDL for uptake by THP-1 macrophages. 
21 
 
Not only non-labeled Acro-LDL but also acetylated LDL compete with DiI-labeled 
Acro-LDL for uptake by THP-1 macrophages, supporting that SR-A1 is mainly involved in 
the uptake of Acro-LDL (Fig. 13). 
 
Intracellular fate of Acro-LDL in THP-1 macrophages 
After uptake by macrophages, LDL is delivered to lysosomes. Thus, we tested 
whether Acro-LDL was also delivered to lysosomes. DiI-labeled Acro-LDL and lysosomes 
stained with LysoTracker were observed with confocal microscopy (Fig. 14). These two 
markers were merged, indicating that Acro-LDL was delivered to lysosome. In the case of 
DiI-OxLDL, two markers were also merged. 
In order to clarify whether protein of Acro-LDL also was delivered to lysosomes, 
lysosome of THP-1 macrophages incubated with Acro-LDL was fractionated by 
centrifugation (Fig. 15). Lysosomal-associated membrane protein 1 (LAMP-1) was used as 
marker protein of lysosomes. Protein-conjugated acrolein was detected stronger in lysosome 
fraction than that in whole homogenate, confirming that Acro-LDL was delivered to 
lysosome. 
After uptake by macrophages, apoB in LDL is degraded in lysosomes [30]. In order 
to clarify whether apoB in Acro-LDL was degraded by protease, apoB in Acro-LDL was 
incubated at pH 4.5 with cell lysate derived from THP-1 macrophages. ApoB in LDL was 
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degraded by lysosomal protease in a time-dependent manner, but apoB in Acro-LDL was 
not hydrolyzed (Fig. 16). The results suggest that apoB in Acro-LDL is cross-linked by 
acrolein and as a result is not susceptible to protease. 
It has been reported that cholesterol in OxLDL accumulated in lysosomes, while 
cholesterol in acetylated LDL accumulated in lipid droplets [11]. When lysosomes and lipid 
droplets in THP-1 macrophages were stained after incubation with Acro-LDL, it is shown 
that THP-1 macrophages accumulated cholesterol in lipid droplets, since Nile Red was not 
merged with LysoTracker (Fig. 17). In the case of OxLDL, cholesterol is accumulated in 
lysosome, since Nile Red was merged with LysoTracker. These results suggest that CE in 
Acro-LDL is hydrolyzed in lysosomes, and FC is delivered to ER, and then accumulated in 
lipid droplets. 
 
Cholesterol metabolism in THP-1 macrophages incubated with Acro-LDL 
Macrophages process exogenous cholesterol delivered by lipoproteins and 
accumulate the cholesterol as CE in lipid droplets. Thus, we evaluated activities of the 
cholesterol metabolic enzymes, ACEase, ACAT and NCEase. Cell lysate was prepared from 
THP-1 macrophages incubated with or without LDL, OxLDL or Acro-LDL for 2 days. Both 
ACEase and ACAT activities were increased by incubation with LDL, OxLDL and 
Acro-LDL either with 2 or 10 mM acrolein (Fig. 18A and 18B). The degree of stimulation in 
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ACEase activity was in the order Acro-LDL (10 mM) ≥ OxLDL > Acro-LDL (2 mM) > LDL, 
and that in ACAT was Acro-LDL (10 mM) > Acro-LDL (2 mM) > OxLDL > LDL. However, 
NCEase activity was similar among all conditions (Fig. 18C). These data indicate that 
cholesterol metabolism functions efficiently in macrophages incubated with Acro-LDL to 
induce storage of cholesteryl ester within lipid droplets. 
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Fig. 3.  Agarose gel electrophoresis of lipoproteins and Acro-lipoproteins. 
Conjugation of 2 mg protein/mL LDL and HDL with 10 mM acrolein was performed as 
described in the Materials and Methods. 
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Detection of malondialdehyde in each lipoprotein were described in Supplemental Methods. 
**P<0.01 by t-test. 
  
Table 1.  Malondialdehyde contents in lipoproteins. 
 Malondialdehyde (nmol/mg protein) 
VLDL  0.857 ± 0.492  
Acro-VLDL  0.815 ± 0.224  
LDL  0.085 ± 0.027  
Acro-LDL  0.067 ± 0.016  
HDL  0.063 ± 0.017   ** 
Acro-HDL  0.065 ± 0.010  
OxLDL  12.369 ± 0.469  
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Fig. 7.  SDS-PAGE and western blot analysis of apoB and protein-conjugated acrolein in 
native LDL, OxLDL and Acro-LDL prepared with 2 and 10 mM acrolein. 
Native LDL was prepared from volunteers over 65-years-old, and both OxLDL and 
Acro-LDL were prepared from the same native LDL. Anti-apoB and anti-acrolein antibodies 
(monoclonal and polyclonal) were used as the primary antibody. 
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Fig. 8.  SDS-PAGE using gradient gel and western blot analysis of apoB and 
protein-conjugated acrolein in native LDL, OxLDL and Acro-LDL prepared with 2 and 10 
mM acrolein. 
Anti-apoB and anti-acrolein antibodies (monoclonal and polyclonal) were used as the 
primary antibody. 
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Fig. 9.  Agarose gel electrophoresis of Acro-LDL. 
Acro-LDL was prepared using the indicated concentration of acrolein.  
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Fig. 10.  Cholesterol contents of THP-1 macrophages incubated with 200 µg protein/mL 
Acro-LDL for 48 h. (-) means THP-1 macrophages incubated without lipoproteins. 
**P<0.01 vs LDL by Dunnett’s test. 
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Fig. 11.  SDS-PAGE and western blot analysis of apoB and protein-conjugated acrolein in 
THP-1 macrophages incubated with Acro-LDL. 
Anti-apoB and anti-acrolein antibodies (monoclonal and polyclonal) were used as the 
primary antibody. 
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Fig. 12.  Analysis of receptor mediating uptake of Acro-LDL by THP-1 macrophages. 
(A) Expression of SR-A1 and CD36 in THP-1 macrophages incubated with 200 µg 
protein/mL Acro-LDL prepared with the indicated concentrations of acrolein for 48 h. (-) 
means THP-1 macrophages incubated without lipoprotein. (B) Effect of anti-SR-A1 and 
CD36 antibodies on uptake of DiI-labeled Acro-LDL and OxLDL. Macrophages were 
pretreated with antibody for 1 h, and then incubated with DiI-labeled lipoproteins in the 
presence of antibody. (-) means THP-1 macrophages incubated without antibody. The 
detailed methods are described in the Materials and Methods. *P<0.05, **P<0.01 vs (-) by 
Dunnett’s test. 
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Fig. 13.  Effect of acetylated LDL on uptake of DiI-labeled Acro-LDL. Macrophages were 
pretreated with RPMI containing 2% FBS for 1 h, and then incubated with 10 µg protein/mL 
DiI-labeled lipoproteins and indicated concentrations of acetylated LDL or Acro-LDL 
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Fig. 14.  Confocal fluorescence microscopy of DiI-labeled lipoproteins and lysosomes. 
THP-1 macrophages were incubated with or without DiI- labeled Acro-LDL or DiI- labeled 
OxLDL for 1 h. DiI was detected in cells (red). Lysosomes were stained with LysoTracker 
(green). Bar; 20 µm. 
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Fig. 15.  Detection of protein-conjugated acrolein in lysosome fraction in THP-1 
macrophages incubated with Acro-LDL. 
Before fractionation by sequential centrifugation, THP-1 macrophages were incubated with 
50 µg protein/mL Acro-LDL for 48 h. 
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Fig. 16.  ApoB digestion by lysosomal enzymes of THP-1 macrophages. LDL and 
Acro-LDL prepared with 2 or 5 mM acrolein were incubated with cell lysate of THP-1 
macrophages at pH 4.5 for the indicated times at 37 °C. The detailed methods were 
described in the Materials and Methods. 
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Fig. 17.  Confocal fluorescence microscopy of lipid droplets and lysosomes. THP-1 
macrophages were incubated with 200 µg protein/mL Acro-LDL or OxLDL for 48 h. 
Macrophages were treated with Nile Red and LysoTracker. Lipid droplets (red) and 
lysosomes (green) were detected in cells. Bar; 20 µm. 
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Discussion 
Macrophage foam cell formation is a hallmark of atherosclerosis, but the 
fundamental cause is still unclear. Acrolein is a highly reactive aldehyde and is produced 
endogenously [12]. It has been reported that protein-conjugated acrolein was detected in 
human atherosclerotic lesions [25], apoB in LDL isolated from healthy subjects [26], and 
plasma from patients with carotid atherosclerosis [27] or hyperlipidemia [28]. From these 
findings, there is a possibility that acrolein conjugate with LDL, and then produced 
Acro-LDL induces macrophage foam cell formation and atherogenesis. Our finding in this 
study indicates that Acro-LDL is one type of atherogenic lipoprotein found in human plasma, 
and that it is taken up into macrophages through the scavenger receptor. 
In this study, Acro-LDL was prepared by incubation of LDL with acrolein. The band 
of Acro-LDL prepared with high concentration of acrolein was broad in agarose gel 
electrophoresis, and the mobility of the band increased. It is known that the mobility of 
particle in agarose gel electrophoresis is affected by both size and charge of the particles. 
Because western blot analysis showed the increase of molecular weight of apoB in 
Acro-LDL, it was expected that size of Acro-LDL was larger than that of LDL. It has been 
reported that 13 FDP-Lys and 87 MP-Lys residues were generated in apoB in LDL by 2 mM 
acrolein modification [26]. Because the positive charge of lysine residues is masked by the 
structure of MP-Lys, Acro-LDL shows a totally negative charge compared with LDL. So, the 
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broad band of Acro-LDL in agarose gel electrophoresis is probably due to the change in size 
and charge of Acro-LDL compared with native LDL. 
In OxLDL, not only lipid peroxidation but also apoB cleavage occured by 
non-enzymatic mechanism [55]. However, the molecular weight of apoB in Acro-LDL 
determined by SDS-PAGE increased compared with apoB in native LDL. The reason for the 
increase of apparent molecular weight of apoB may depend on cross-links between cysteine 
and lysine residues [42, 43] or histidine and lysine residues [44]. Accordingly, characteristics 
of Acro-LDL might be quite different from that of OxLDL. 
It has been reported that acetylated LDL upregulated the expression of SR-A1 [56]. 
Our results also showed that protein levels of SR-A1 were changed by incubation with 
Acro-LDL. The results suggest that the same mechanism works in macrophage. In order to 
clarify whether SR-A1 contribute uptake of Acro-LDL in macrophage, we did inhibition 
assay using neutralizing antibody. The results indicate that SR-A1 dependent endocytic route 
was a major route. But about 20% of the uptake was maintained under the existence of 
anti-SR-A1 antibody, suggesting that other pathway such as phagocytosis of larger particle 
might be involved in the uptake of Acro-LDL by macrophage. 
It has been reported that OxLDL caused mostly cholesterol accumulation in 
lysosomes [5], while acetylated LDL caused mostly cholesterol accumulation in lipid 
droplets [11]. In the case of Acro-LDL, lipid droplets presented in THP-1 macrophages 
43 
 
incubated with Acro-LDL. The result suggests that the cholesterol metabolism pathway 
functions efficiently, and cholesteryl ester from Acro-LDL is metabolized in macrophage and 
is stored in lipid droplets like cholesteryl ester from acetylated LDL. 
Acrolein was produced by polyamine oxidation, and polyamines present in cells at 
millimolar concentrations. When cell damages occur, polyamines are released from the cells 
and oxidized, producing acrolein. It has been reported that acrolein is associated with several 
chronic diseases such as chronic renal failure [13], stroke [14-16], Alzheimer's disease [17] 
and Sjögren's syndrome [57]. There are also reports that carotid atherosclerosis is well 
correlated to protein-conjugated acrolein levels [27], and protein-conjugated acrolein is 
detected in LDL from human plasma [26] and human atherosclerotic tissue [25]. Indeed, we 
also confirmed acrolein-conjugated apoB in intact LDL using anti-acrolein antibody. 
Moreover, it has been reported that healthy subjects show some protein-conjugated acrolein 
levels in plasma [13]. Therefore, it is expected that high concentration of acrolein was 
released at local site of cell damage and Acro-LDL is produced at the site. Our results show 
that acrolein contributes to development of atherosclerosis through macrophages foam cell 
formation by Acro-LDL. 
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Conclusion 
In the present study, we examined whether Acro-LDL is effectively taken up into 
macrophages converting them into foam cells. Our investigation about Acro-LDL showed 
that acrolein cross-linked apoB in Acro-LDL and changed charge of Acro-LDL more 
negative than that of LDL. In cell culture study, Acro-LDL induced higher cholesterol 
accumulation in THP-1 macrophages than OxLDL through uptake via SR-A1 pathway, and 
cholesteryl ester was stored in lipid droplets in THP-1 macrophages incubated with 
Acro-LDL. These results show that Acro-LDL is one of atherogenic lipoprotein found in 
human plasma, and that it is taken up into macrophages through the scavenger receptor, 
resulting to macrophage foam cell formation. Our study suggests that acrolein contributes to 
development of atherosclerosis through macrophages foam cell formation by Acro-LDL. 
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